Anti-Mi-2 antibody-positive juvenile dermatomyositis(JDM) is considered as a good prognostic
inflammatory myositis for which steroid drug is effective. Although it is relatively rare in Japanese JDM, and it is
also clarified that a steroid-resistant and intractable phenotype is occasionally present by our report. In such
patients with steroid-resistant anti-Mi-2 antibody-positive JDM, we conclude that IVIG might be useful as a
second-line drug.